ARTICLE | Clinical News
Sparlon modafinil regulatory update
October 24, 2005 7:00 AM UTC
CEPH received an approvable letter from FDA for an sNDA for Sparlon modafinil to treat attention deficit hyperactivity disorder (ADHD) in children and adolescents ages 6 through 17. CEPH hopes to laun...